U.S. FDA Approves BAVENCIO® (avelumab) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy

Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

July 2, 2020

On June 30, 2020, Pfizer announced with our partner Merck KGaA that the U.S. Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

The approval is based on results from the Phase III JAVELIN Bladder 100 study, which were presented at the ASCO20 Virtual Scientific Meeting in May.